Clinical Data on Thalidomide Reported in Recurrent Epithelial Ovarian Cancer
3rd Nov 2005, 18:10 GMT
Oral Presentation at the Chemotherapy Foundation Symposium Reported 50% of Patients Achieved Overall Response in Median Progression Free Survival
Clinical Data on Thalidomide Reported in Recurrent Epithelial Ovarian Cancer related news:
- Gene expression profile helps predict chemotherapy response in ovarian cancer patients — EurekAlert! - Cancer
- Phase I Study of High Dose Weekly ABRAXANE Published in Journal of Clinical Oncology: Responses Achieved in Patients With Taxol Refractory Ovarian Cancer and Lung Cancer — Radiology News from StratCenter.com
- BSD Medical's Cancer Therapy Makes Hot News — Radiology News from StratCenter.com
- Clinical Data to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference — Rednova News - Health
- Cancer Message — Rednova News - Health
- Cancer screening trial can begin — BBC News | England | Bristol | UK Edition
- Recurrent Yeast Infections Associated with Chronic Stress — Health News Online - Medical and health information and tools from Armenian Medical Network
- Clinical trials with immunotherapy for breast and colorectal cancer, Mount Sinai School of Medicine — Medical News Today RSS/XML Feed
- Journal of Clinical Oncology Publishes Pivotal Phase III Study Reporting Superior Response Rate of ABRAXANE Compared With Taxol in Women With Metastatic Breast Cancer — Radiology News from StratCenter.com
- Cancer Patients Testify on Clinical Trial Coverage — madison.com - RSS
Latest news from Obstetrics/ Gynecology News from StratCenter.com:
- Acusphere Reports Q3 2006 Financial Results and Accomplishments
- CuraGen and TopoTarget Announce Initiation of NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer
- Twin Cities Takes Action to Save Babies
- Substantial Regression of Atherosclerosis May Help Improve Diseased Arteries
- EDAP TMS SA to Participate in Int'l Urology Conferences
- Misonix Showcases SonicOne Ultrasonic Wound Debrider with Medline at MEDICA 2006 in Germany
- 8 Studies Evaluating Cytyc's Novasure System Presented at AAGL Meeting